Terms: = Colorectal cancer AND CEP17
4 results:
1. HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteria.
Sun Q; Li Q; Gao F; Wu H; Fu Y; Yang J; Fan X; Cui X; Pu X
J Cancer Res Clin Oncol; 2023 Feb; 149(2):579-592. PubMed ID: 36018511
[TBL] [Abstract] [Full Text] [Related]
2. Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/cep17 Ratio in HER2-Amplified Early Breast cancer.
Singer CF; Tan YY; Fitzal F; Steger GG; Egle D; Reiner A; Rudas M; Moinfar F; Gruber C; Petru E; Bartsch R; Tendl KA; Fuchs D; Seifert M; Exner R; Balic M; Bago-Horvath Z; Filipits M; Gnant M;
Clin Cancer Res; 2017 Jul; 23(14):3676-3683. PubMed ID: 28143867
[No Abstract] [Full Text] [Related]
3. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.
Martin V; Landi L; Molinari F; Fountzilas G; Geva R; Riva A; Saletti P; De Dosso S; Spitale A; Tejpar S; Kalogeras KT; Mazzucchelli L; Frattini M; Cappuzzo F
Br J Cancer; 2013 Feb; 108(3):668-75. PubMed ID: 23348520
[TBL] [Abstract] [Full Text] [Related]
4. Genomic instability and oncogene amplifications in colorectal adenomas predict recurrence and synchronous carcinoma.
Habermann JK; Brucker CA; Freitag-Wolf S; Heselmeyer-Haddad K; Krüger S; Barenboim L; Downing T; Bruch HP; Auer G; Roblick UJ; Ried T
Mod Pathol; 2011 Apr; 24(4):542-55. PubMed ID: 21102417
[TBL] [Abstract] [Full Text] [Related]
